Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Top General Cardiology and Prevention News of 2022

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

TCTMD’s Top 10 Most Popular Stories for April 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

May 02, 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.